Poxviruses as vaccine vectors

Jenner, 1978

Jenner, 1799

Bazin, 2000

Fenner, 1988

Beale, 2002, Bioterrorism: what can we do?, J R Soc Med, 95, 47, 10.1258/jrsm.95.10.479

Mackett, 1985, The construction and characterisation of vaccinia virus recombinants expressing foreign genes, 191

Panicali, 1982, Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus, Proc Natl Acad Sci USA, 79, 4927, 10.1073/pnas.79.16.4927

Binns, 1992

Moss, 1996, Genetically engineered poxviruses for recombinant gene expression, vaccination and safety, Proc Natl Acad Sci USA, 93, 11341, 10.1073/pnas.93.21.11341

Paoletti, 1995, Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC, Dev Biol Stand, 84, 159

Paoletti, 1996, Applications of pox virus vectors to vaccination: an update, Proc Natl Acad Sci USA, 93, 11349, 10.1073/pnas.93.21.11349

Moss, 1996, Poxviridae: the viruses and their replication, 2637

Fenner, 1996, Poxviruses, 2673

Baxby, 1981

Pastoret, 1996, Stability of recombinant vaccinia-rabies vaccine in veterinary use, Dev Biol Stand, 87, 245

Baxby, 1994, Human cowpox 1969–93: a review based on 54 cases, Br J Dermatol, 131, 598, 10.1111/j.1365-2133.1994.tb04969.x

Pattyn, 2000, Monkeypoxvirus infections, Revue Scientifique et Technique de l'Office International des Epizooties, 19, 92, 10.20506/rst.19.1.1207

Goebel, 1990, The complete DNA sequence of vaccinia virus, Virology, 179, 247, 10.1016/0042-6822(90)90294-2

Shchelkunov, 1993, Genes of variola and vaccinia viruses necessary to overcome the host protective mechanisms, FEBS Lett, 319, 80, 10.1016/0014-5793(93)80041-R

Shchelkunov, 1993, Comparison of the genetic maps of variola and vaccinia viruses, FEBS Lett, 327, 321, 10.1016/0014-5793(93)81013-P

Paoletti, 1984, Construction of live vaccinia viruses using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D, Proc Natl Acad Sci USA, 81, 193, 10.1073/pnas.81.1.193

Collier, 1955, The development of a stable smallpox vaccine, J Hyg, 53, 76, 10.1017/S002217240000053X

Gherardi, 1999, Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants, Vaccine, 17, 1074, 10.1016/S0264-410X(98)00324-7

Pastoret, 1996, The development and use of vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies: a link between Jenner and Pasteur, Epidemiol Infect, 116, 235, 10.1017/S0950268800052535

Smith, 1983, Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen, Nature, 302, 490, 10.1038/302490a0

Smith, 1983, Construction and characterisation of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters, Proc Natl Acad Sci USA, 80, 7155, 10.1073/pnas.80.23.7155

Perkus, 1991, Deletion of 55 open reading frames from the termini of vaccinia virus, Virology, 180, 406, 10.1016/0042-6822(91)90047-F

Perkus, 1985, Recombinant vaccinia virus: immunization against multiple pathogens, Science, 229, 981, 10.1126/science.2992092

Cooney, 1991, Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein, Lancet, 337, 567, 10.1016/0140-6736(91)91636-9

Cooney, 1993, Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein, Proc Natl Acad Sci USA, 90, 1882, 10.1073/pnas.90.5.1882

Kundig, 1993, Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination, Vaccine, 11, 1154, 10.1016/0264-410X(93)90079-D

Flexner, 1988, Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen, Nature, 335, 259, 10.1038/335259a0

Ramirez, 2000, Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of pre-existing immunity to the vector, J Virol, 74, 7651, 10.1128/JVI.74.16.7651-7655.2000

Cohen, 2001, Smallpox vaccinations: how much protection remains?, Science, 294, 985, 10.1126/science.294.5544.985

Lane, 1971, Risks of smallpox vaccination complications in the United States, Am J Epidemiol, 93, 238, 10.1093/oxfordjournals.aje.a121252

Lane, 1969, Complications of smallpox vaccination, 1968. National surveillance in the United States, N Engl J Med, 281, 1201, 10.1056/NEJM196911272812201

Lane, 1970, Complications of smallpox vaccination 1968: results of ten statewide surveys, J Infect Dis, 122, 303, 10.1093/infdis/122.4.303

Mayr, 1978, The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism, Zentralbe Bakteriol, 167, 375

Kieny, 1984, Expression of rabies virus glycoprotein from a recombinant vaccinia virus, Nature, 312, 163, 10.1038/312163a0

Alcami, 1996, A mechanism for the inhibition of fever by a virus, Proc Natl Acad Sci USA, 93, 11029, 10.1073/pnas.93.20.11029

Tartaglia, 1992, NYVAC: a highly attenuated strain of vaccinia virus, Virology, 188, 217, 10.1016/0042-6822(92)90752-B

Brockmeier, 1993, Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses, Vet Microbiol, 38, 41, 10.1016/0378-1135(93)90074-H

Paoletti, 1994, Safe and effective poxvirus vectors—NYVAC and ALVAC, Dev Biol Stand, 82, 65

Tartaglia, 1994, Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strains, NYVAC, Dev Biol Stand, 82, 125

Welter, 2000, Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines, J Virol, 74, 6358, 10.1128/JVI.74.14.6358-6367.2000

Hochstein-Mintzel, 1975, An attenuated strain of vaccinia virus (MVA) Successful intramuscular immunisation against vaccinia and variola (author's transl), Zentralbl Bakteriol [Orig A], 230, 283

Sutter, 1992, Non-replicating vaccinia vector efficiently expresses recombinant genes, Proc Natl Acad Sci USA, 89, 10847, 10.1073/pnas.89.22.10847

Antoine, 1998, The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses, Virology, 244, 365, 10.1006/viro.1998.9123

Carroll, 1997, Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model, Vaccine, 15, 387, 10.1016/S0264-410X(96)00195-8

Flexner, 1987, Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression, Nature, 330, 259, 10.1038/330259a0

Karupiah, 1990, Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2, J Immunol, 144, 290, 10.4049/jimmunol.144.1.290

Brochier, 1989, Use of recombinant vaccinia-rabies virus for oral vaccination of wildlife against rabies: immunity to several non-target bait-consuming species, J Wild Dis, 25, 540, 10.7589/0090-3558-25.4.540

Pastoret, 1995, Environmental safety assessment of vaccines derived from biotechnology, Rev Sci Tech O.I.E, 14, 963, 10.20506/rst.14.4.887

Rupprecht, 2001, Human infection due to recombinant vaccinia-rabies glycoprotein virus, N Engl J Med, 345, 582, 10.1056/NEJMoa010560

Ball, 1987, High-frequency homologous recombination in vaccinia virus DNA, J Virol, 61, 1788, 10.1128/JVI.61.6.1788-1795.1987

Chernos, 1985, Recombinants between vaccinia and ectromelia viruses bearing the specific pathogenicity markers of both parents, J Gen Virol, 66, 621, 10.1099/0022-1317-66-3-621

Chernos, 1987, Biologic properties and genome structure of the recombinants between ectromelia and rabbitpox viruses, Acta Virol, 31, 193

Boulanger, 1995, Comparison of the susceptibility of the red fox (Vulpes vulpes) to a vaccinia-rabies recombinant virus and to cowpox virus, Vaccine, 13, 215, 10.1016/0264-410X(95)93139-Z

Thomas, 1990, Primary multiplication site of the vaccinia-rabies glycoprotein recombinant virus administered to foxes by the oral route, J Gen Virol, 71, 37, 10.1099/0022-1317-71-1-37

Mayr, 1966, Attenuation of virulent fowl pox virus in tissue culture and characteristics of the attenuated virus, Zentralbl Veterinarmed [B], 13, 1, 10.1111/j.1439-0450.1966.tb00871.x

Taylor, 1988, fowlpox virus as a vector in non-avian species, Vaccine, 6, 466, 10.1016/0264-410X(88)90091-6

Taylor, 1991, Efficacy studies on a canarypox–rabies recombinant virus, Vaccine, 9, 190, 10.1016/0264-410X(91)90152-V

Kerr, 1995, Myxoma virus as a vaccine vector for rabbits: antibody levels to influenza virus haemagglutinin presented by a recombinant myxoma virus, Vaccine, 13, 1722, 10.1016/0264-410X(95)00113-F

Tripathy, 1999, Swinepox virus as a vaccine vector for swine pathogens, Adv Vet Med, 41, 463, 10.1016/S0065-3519(99)80035-4

Berhe, 2003, Development of a dual recombinant vaccinia to protect small ruminants against peste des petits ruminants and capripox infections, J Virol, 10.1128/JVI.77.2.1571-1577.2003

Blancou, 1986, Oral vaccination of the fox against rabies using a live recombinant vaccinia virus, Nature, 322, 373, 10.1038/322373a0

Pastoret, 1992, Recombinant poxviruses

Pastoret, 1988, First field trial of fox vaccination against rabies with a vaccinia–rabies recombinant virus, Vet Rec, 123, 481, 10.1136/vr.123.19.481

Brochier, 1991, Large-scale eradication of rabies with a recombinant vaccinia–rabies virus, Nature, 354, 520, 10.1038/354520a0

Brochier, 2001, Elimination de la rage en Belgique par la vaccination du renard roux (Vulpes vulpes), Ann Med Vet, 145, 293